Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by WORKINMONTANAon May 17, 2020 6:13pm

281 Views

Post# 31040474

Le cannabis pourrait être efficace contre le coronavir

Des chercheurs canadiens spcialiss dans le cannabis affirment qu’un mdicament base d’un composant du cannabis pourrait confrer une rsistance au coronavirus (Covid-19), rvlait Deutsche Welle le 8 mai.

La recherche d’un vaccin ou d’un traitement contre le Covid-19 pousse les chercheurs explorer de nouvelles voies moins conventionnelles. Alors qu’Isral a lanc en avril dernier des essais cliniques pour traiter le coronavirus l’aide du cannabis, c’est maintenant au tour des Canadiens de se pencher sur les atouts de la weed.

LIEN>>>le-cannabis-pourrait-etre-efficace-contre-le-coronavirus